Skip to content

Neuroplasticity

The brain's capacity to reorganize, a leading candidate mechanism for the lasting effects of psychedelics and learning.

State of the evidence

Synthesized

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Neuroplasticity, neural plasticity, brain plasticity, synaptic plasticity, neurogenesis, then ranked by relevance.

Research indicates that both meditation and psychedelic compounds can induce neuroplastic changes, including increased cortical thickness, dendritic spine formation, and altered brain network connectivity. However, evidence is mixed regarding the durability and context-dependence of these effects, with some studies showing lasting changes and others showing transient or inconsistent results. The main caveat is that many studies are small, observational, or preclinical, limiting generalizability.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.

Meditation practitioners had greater cortical thickness in the prefrontal cortex and right anterior insula compared to controls, with the prefrontal difference most pronounced in older participants, and thickness in two regions correlated with meditation experience.

observational cohort Sample size: 20

Serotonergic psychedelics robustly increased neuritogenesis and spinogenesis in the prefrontal cortex via TrkB, mTOR, and 5-HT2A signaling pathways.

laboratory study

Brain activation in sustained attention regions showed an inverted u-shaped curve with meditation expertise, and experts showed less activation in discursive thought regions and more in response inhibition regions during distracter sounds.

observational cohort

Psilocybin treatment decreased amygdala cerebral blood flow and increased default-mode network connectivity, with specific connectivity changes predicting clinical response at five weeks.

observational cohort Sample size: 19

Chronic pain was associated with decreased connectivity of medial prefrontal cortex to posterior default mode network regions and increased connectivity to insular cortex, with changes correlated to pain intensity and duration.

observational cohort

Intracellular 5-HT2ARs, not cell-surface ones, mediate the plasticity-promoting effects of psychedelics, explaining why serotonin does not engage similar plasticity mechanisms.

experimental study

Psychedelics directly bind to TrkB with high affinity to produce antidepressant-like effects independently of serotonin 2A receptor activation.

experimental study

Psilocybin's antidepressant action correlated with global increases in brain network integration, as indicated by decreased fMRI brain network modularity.

open-label trial and double-blind phase II randomized controlled trial

Mindfulness training reduced affective Stroop conflict and increased dorsolateral prefrontal cortex responses during executive processing, but only participants with the greatest amount of practice showed improvements in response inhibition and increased recruitment of anterior cingulate, medial prefrontal, and insular regions during negative valence processing.

randomized controlled trial

Psilocybin reduced negative affect and amygdala reactivity at one week, but negative affect and amygdala response returned to baseline at one month while positive affect remained elevated and resting-state functional connections increased.

open-label pilot study Sample size: 12

Ketamine rapidly induces synaptogenesis and spine formation in the prefrontal cortex via stimulation of the mammalian target of the rapamycin signaling pathway, reversing stress-induced atrophy and producing rapid antidepressant effects.

review

Psilocybin therapy increased cognitive flexibility for at least four weeks, but greater increases in neural flexibility between the ACC and PCC were associated with less improvement in cognitive flexibility.

open-label study Sample size: 24

LSD-induced increases in brain entropy predicted lasting increases in the personality trait openness two weeks later, especially during music listening and when ego dissolution was reported.

balanced-order, placebo-controlled study Sample size: 19

Psychedelics promote neuroplasticity through mechanisms including dendritogenesis, synaptogenesis, neurogenesis, and expression of plasticity-related genes, particularly in the prefrontal cortex and hippocampus.

review

LSD increased effective connectivity from the thalamus to the posterior cingulate cortex via serotonin 2A receptor activation and decreased connectivity from the ventral striatum to the thalamus independently of those receptors.

double-blind, randomized, placebo-controlled, cross-over study Sample size: 25

The BDNF/CREB signaling pathway serves as a core hub mediating multisystem network dysfunction in depression, integrating emotional-cognitive circuits, HPA axis activity, neurotransmitter systems, and neuroplasticity.

review

Classic psychedelics affect behavioral domains overlapping with ASD phenotypes through neurobiological mechanisms that converge with alterations implicated in ASD, but direct evidence from validated animal models of ASD is scarce.

review

Blocking CX3CL1/CX3CR1 signaling prevents ketamine's antidepressant-like behavioral effects and its enhancement of synaptic plasticity in mice.

animal study

Psilocybin transiently increases dendritic calcium event rates in apical tufts in a brain state- and 5-HT2A receptor-dependent manner, and alters the predictive relationship between acute dendritic calcium signaling and subsequent spine formation.

experimental study

Proposes a descriptive framework, Post-Perturbation Integrative Neuroplasticity, to characterize broad cross-domain cognitive reorganization following significant perturbation events, distinguishing it from pathological conditions and post-traumatic growth.

theoretical or philosophical paper

Ketamine and esketamine have the strongest evidence among rapid-acting antidepressant interventions for treatment-resistant depression, while psilocybin-assisted therapy shows promise but remains investigational.

review

Psilocybin's effect on synaptic density is modulated by environmental context, with a therapeutic-like setting associated with greater increases in synaptic density and more intense mystical-type experiences than an MRI scanner setting.

observational cohort Sample size: 15

Ketamine and MDMA induce peripheral DNA methylation changes that converge on neuroplasticity and neuroimmune pathways.

clinical trial Sample size: 36

Ketamine combined with psychotherapy shows promising reductions in craving and increases in abstinent days for alcohol and cocaine use disorders, but effects on relapse prevention are inconsistent and the drug carries a well-established risk of misuse.

narrative review

Proposes that Christian commitment and practice may yield dedicated neural structures or networks over time and foster interplay with secular cognition, and outlines hypotheses and methods to test this.

theoretical or philosophical paper

Points of agreement

  • Meditation and psychedelics are associated with structural and functional brain changes, including increased cortical thickness, dendritic spine density, and altered network connectivity.
  • Psychedelics promote neuroplasticity through mechanisms involving BDNF/TrkB signaling, 5-HT2A receptors, and synaptic protein synthesis.
  • Psilocybin and ketamine show rapid antidepressant effects that correlate with changes in brain network integration and synaptic plasticity.
  • The effects of psychedelics on neuroplasticity are context-dependent, with environmental setting influencing outcomes.

Conflicts

  • Some studies report lasting increases in neuroplasticity markers (e.g., cortical thickness, synaptic density) while others find no significant overall effect or return to baseline.
  • The role of 5-HT2A receptor activation in psychedelic-induced plasticity is debated: one study shows it is essential, while another shows TrkB binding is sufficient and independent of 5-HT2A.
  • In meditation research, the relationship between practice hours and brain activation is non-linear (inverted u-shaped), suggesting conflicting patterns of expertise-related plasticity.

Gaps

  • Durability of neuroplastic changes beyond a few weeks is largely unstudied.
  • Most psychedelic studies are small, open-label, or preclinical, lacking large randomized controlled trials.
  • The influence of dose, route of administration, and environmental context on neuroplastic outcomes is not fully characterized.
  • Direct evidence in clinical populations (e.g., depression, addiction) is limited, especially for long-term outcomes.
  • The relationship between molecular markers of plasticity and behavioral or clinical improvements remains unclear.
Browse these studies in the library
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Neuroplasticity, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Neuroplasticity or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

Latest monthly recap: July 2026 →

1,405 articles · 798 from the last two years · 30,552 participants across 195 studies reporting sample size

Common study designs

review 421 experimental study 109 observational cohort 62 randomized controlled trial 58 theoretical or philosophical paper 202

Psilocybin and Chronic Neuropathic and Centralized Pain: Converging Mechanisms in Central Sensitization, Neuroplasticity, and Network Organization

Anesthesia Research September 11, 2026 M. S. Neves, C. T. P. Gusmão, Raimundo Chiyo et al.

Background/Objectives: Neuropathic and chronic centralized pain disorders remain difficult to treat because they involve central sensitization, maladaptive neuroplasticity, neuroimmune activation, affective amplification, and large-scale network dysfunction. Psilocybin, a serotonergic psychedelic acting primarily through 5-HT2A receptor agonism, has emerged as a candidate modulator of chronic...

515. Influence of the context of administration on 5-MeO-DMT-promoted antidepressant-like effects and neuroplasticity

International Journal of Neuropsychopharmacology September 9, 2026 Romain Hacquet, P Pantiya, G Gotti et al.

Abstract Background Psychedelics such as psilocybin have demonstrated rapid and sustained antidepressant effects in humans, particularly when administered in carefully designed therapeutic environments (Borkel et al., 2024; Carhart-Harris et al., 2021). DMT and 5-MeO-DMT, distinguished by their brief duration of psychedelic effects, have also shown encouraging preliminary outcomes in depressive...

753. The Mechanism of Ketamine’s Anti-Suicidal Action: From Glutamatergic Surge to Neuroplasticity via the Opioid-Attachment Interface

International Journal of Neuropsychopharmacology September 9, 2026 A Solomon, Y Domany

Abstract Background A critical gap exists in understanding the biological mechanism linking ketamine’s rapid anti-suicidal effects to the Interpersonal Theory of Suicide (IPTS). While the "Kinetic Mismatch" between acute relief and delayed synaptogenesis is well-known, current models overlook how ketamine modulates “Thwarted Belongingness” (a core IPTS pillar) and the attachment anxiety that...

860. Glutamatergic Signaling and Neuroplasticity in Mood Disorders: A Historical Perspective from Preclinical Discoveries to Clinical Translation

International Journal of Neuropsychopharmacology September 9, 2026 Gabriella Gobbi

Abstract Background While the monoaminergic hypothesis has long dominated the treatment of mood disorders, its limitations have prompted the exploration of alternative mechanisms. Early work by Skolnick et al. (1996) demonstrated that chronic antidepressant treatment induces adaptive changes in N-methyl-D-aspartate (NMDA) receptors, suggesting glutamatergic signaling as a convergent pathway in...

The mPFC-reuniens-hippocampus pathway links brain circuitry and neural plasticity in antidepressant response

Nature Communications September 1, 2026 Maxime Veleanu, Louise E. Schuberth, Antje Kilias et al.

The pathophysiology of depression involves multiple biological processes, including circuit dysfunction and impaired neuroplasticity, yet an integrative view linking these processes remains elusive. Here, we identify a convergent circuit for antidepressant response and plasticity modulation. We demonstrate that chemogenetic activation of the infralimbic cortex (IL) exerts rapid...

Antidepressant-like effects of ketamine involve CX3CL1/CX3CR1 signaling-mediated synaptic plasticity in the mPFC

Translational Psychiatry July 20, 2026 Yong-Yu Yin, Si-Rui Sun, Hui-Ying Zhang et al.

Ketamine, a non-competitive N-methyl-D-aspartate acid (NMDA) receptor antagonist, produces rapid and sustained antidepressant actions, but the underlying molecular mechanism remains unclear. The CX 3 CL1/CX 3 CR1 signaling is closely related to mood disorders, and this study aims to investigate its role in ketamine’s antidepressant actions. We pharmacologically (AZD8797, a selective CX 3 CR1...

Post-Perturbation Integrative Neuroplasticity (PPIN): A Descriptive Framework for Non-Pathological Cross-Domain Cognitive Reorganization

Zenodo (CERN European Organization for Nuclear Research) July 18, 2026 Aziel Eliab

Post-Perturbation Integrative Neuroplasticity (PPIN) is a descriptive framework for sustained, non-pathological cognitive reorganization following significant perturbation events such as severe trauma, near-death experiences, or extreme stress. Unlike acquired savant syndrome, which typically produces narrow, domain-specific skill emergence, PPIN describes broad cross-domain integration,...

Psilocybin's effect on human brain synaptic plasticity.

Translational Psychiatry July 15, 2026 Annette Johansen, Pontus Plavén-sigray, Martin K Madsen et al.

Psychedelics such as psilocybin have been linked to enhanced neuroplasticity and symptom relief in affective disorders, but the neurobiological mechanisms and impact of environmental context remain unclear. Here, we tested whether a single dose of psilocybin (0.3 mg/kg) alters synaptic density in healthy individuals and whether setting-dependent subjective experience shapes this effect. Fifteen...

Brain and Environment Interaction: Neuroplasticity of the Visual Cortex and the Roles of Sensory Deprivation, Sleep, and Dreams.

Psychiatry July 6, 2026 Rehana K Naik Olson, Lawrence Wichlinski

Neuroplasticity refers to the tendency of the nervous system to change structurally and functionally due to experience. The adult visual cortex was historically presumed rigid and unchangeable. However, recent research has identified residual neuroplasticity in the visual cortex extending into adulthood, which may be mediated by environmental factors including visual deprivation. Eagleman and...

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.

Pharmacology, biochemistry, and behavior June 30, 2026 Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.

Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without...

Clinical trials

All Neuroplasticity trials →